Lee Babiss, head of preclinical R&D for Hoffman-LaRoche, told an audience at the Genome Tri-Conference in February that between 1996 and 1999, big pharma doubled the number of targets under scrutiny. But the new flood of targets is not accompanied by a flood of data. Each target is much less documented with literature references than in the past, he says.

Percent of targets in the typical pharmaceutical company’s portfolio that are culled from the scientific literature: 90

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.